Get all premium features to the best stock analysis tool

Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.

Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript

Enovis (ENOV) came out with quarterly earnings of $0.9 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago.

Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales grew 8% on a reported basis, 6% organic Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion Dallas, TX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.